聖湘生物(688289.SH):擬與關聯方產業基金及聖維星耀共同投資紅岸基元
格隆匯2月25日丨聖湘生物(688289.SH)公佈,為進一步落實公司戰略規劃,保持綜合競爭力,加速打造生命健康領域多元化平台型企業,公司於2025年2月25日召開第二屆董事會2025年第三次臨時會議,審議通過了《聖湘生物科技股份有限公司關於收購股權暨與關聯方共同投資的議案》。同意公司與關聯方產業基金及聖維星耀共同投資紅岸基元,其中,公司以自有資金合計投資7,560萬元,通過受讓股權及增資交易後,將持有目標公司54%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.